Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $91.0 million.

  • Avidity Biosciences' Other Non-Current Assets rose 315731.66% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 315731.66%. This contributed to the annual value of $2.8 million for FY2024, which is 82857.14% up from last year.
  • Per Avidity Biosciences' latest filing, its Other Non-Current Assets stood at $91.0 million for Q3 2025, which was up 315731.66% from $90.8 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Other Non-Current Assets high stood at $91.0 million for Q3 2025, and its period low was $301000.0 during Q4 2023.
  • Over the past 5 years, Avidity Biosciences' median Other Non-Current Assets value was $523000.0 (recorded in 2022), while the average stood at $10.5 million.
  • As far as peak fluctuations go, Avidity Biosciences' Other Non-Current Assets crashed by 4966.56% in 2023, and later surged by 315731.66% in 2025.
  • Quarter analysis of 5 years shows Avidity Biosciences' Other Non-Current Assets stood at $599000.0 in 2021, then fell by 0.17% to $598000.0 in 2022, then crashed by 49.67% to $301000.0 in 2023, then skyrocketed by 828.57% to $2.8 million in 2024, then skyrocketed by 3157.32% to $91.0 million in 2025.
  • Its Other Non-Current Assets was $91.0 million in Q3 2025, compared to $90.8 million in Q2 2025 and $2.8 million in Q1 2025.